Cannabis Industry Pivots to Medical Markets After April 2026 Rescheduling Order

In the past 48 hours, the US cannabis industry grapples with regulatory turbulence from the Department of Justice's April 23, 2026, order rescheduling only medical cannabis to Schedule III, leaving adult-use markets in limbo and sparking market volatility.[1] This partial win promises relief from the burdensome 280E tax rule, potentially unlocking deductions and banking access long denied to operators, though full implementation remains uncertain.[6][12] Mergers and acquisitions surged last week, with April 15 marking a frenzy: Aurora Cannabis acquired Ontario's Safari Flower Company for 26.5 million dollars to boost EU GMP-certified output for Germany, Australia, Poland, and the UK; Tilray entered the UK clinical market via Lyphe; and Organigram closed its 107.3 million euro purchase of Germany's Sanity Group, the largest North American buy of a European operator since 2021, with up to 221 million euros possible including earnouts.[2] These moves prioritize medical cannabis amid rescheduling's spotlight on that segment.[2] Enforcement cracked down on illicit operations, as federal indictments charged 51 defendants in an Oklahoma black-market conspiracy spanning March 2025 to April 2026, seizing 61,000 plants and 550 kilograms of processed marijuana across multiple states.[3] Stocks reflected optimism, with Tilray Brands, Akanda, and Canopy Growth topping trading volume on April 28.[4] In New Zealand, a survey showed cannabis prices dropping 22 percent since 2017 to 1,020 dollars per ounce in 2024, fueled by legal medicinal competition making it cheaper and more available than ever.[5] Germany's medical prescriptions exploded 3,300 percent from 2024 to 2025 via reforms and telemedicine.[8] Leaders like Aurora, now with 154 million Canadian dollars cash post-100 million equity raise, are expanding internationally to counter US uncertainty.[2] Compared to prior weeks' quieter consolidation, this M&A wave and rescheduling jolt signal accelerated pivots to medical and global markets, contrasting stalled adult-use progress.[1][2] North Carolina eyes medical legalization in response.[11] Overall, opportunity mixes with caution as taxes ease but federal adult-use reform lags. (348 words) For great deals today, check out https://amzn.to/44ci4hQ This content was created in partnership and with the help of Artificial Intelligence AI.